REDEFINE 2 -- CagriSema in T2D (Lingvay et al., 2025): Significant weight loss and glycemic improvement in adults with overweight/obesity and type 2 diabetes
Clinical trial safety data: In the Phase 2 trial, adverse events were comparable to placebo
A 2025 review described BPC-157 as a peptide with pleiotropic beneficial effects across preclinical models of tissue injury and inflammatory bowel disease
61 : 54325440 Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ and Chen Z (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I
It is generally considered safe to consume through food when glutathione, naturally produced by the body, is not sufficient
Produced under strict pharmaceutical-grade standards $170.00Purchase & earn 170 points